Skin Cancer News and Research

Latest Skin Cancer News and Research

Vismodegib team wins Drug Discovery of the Year award

The British Pharmacological Society proudly announces that its first annual Drug Discovery of the Year award has been won by the discovery team developing vismodegib for the treatment of basal cell carcinoma (a type of skin cancer).

19 Dec 2012

Bayer files radium-223 NDA with FDA for treatment of CRPC patients with bone metastases

Bayer HealthCare today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for radium Ra 223 dichloride (radium-223), an investigational compound for the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases.

15 Dec 2012

Janssen receives FDA approval for ZYTIGA to treat metastatic castration-resistant prostate cancer

Janssen announced today that the U.S. Food and Drug Administration (FDA) has approved a broader indication for the oral, once-daily medication ZYTIGA (abiraterone acetate).

10 Dec 2012

Noncoding DNA sequence required for epidermal differentiation

The differentiation of human epidermis is controlled and stabilized by a long noncoding RNA termed terminal differentiation-induced noncoding RNA acting through a post-transcriptional mechanism, the results of an innovative US study indicate.

7 Dec 2012

Children's eyes at greater risk for permanent damage from sunlight

Anderson Cooper, host of "Anderson Live," was temporarily blinded for 36 hours following a two-hour boat trip in Portugal where the sun damaged and burnt his cornea. Eye health concerns like cataracts, skin cancer of the eyelids and melanoma in the retina can all result from sun-damaged eyes.

7 Dec 2012

Highlights for December 2012 issue of GSA’s Genetics journal

Listed below are the selected highlights for the December 2012 issue of the Genetics Society of America's journal, Genetics.

5 Dec 2012

Study: Risk for skin cancer involves numerous genetic factors

It's common knowledge that excessive UV exposure from sunlight raises your chances for skin cancer, but predicting whether someone will actually develop skin cancer remains difficult. In a new research report, scientists from the University of Alabama at Birmingham (UAB) and the University of Wisconsin-Madison show that the risk for skin cancer involves numerous genetic factors including family history, ethnicity, and genetic variations specific to each individual.

5 Dec 2012

TINCR molecule plays a master role in epidermal differentiation

The surface of your skin, called the epidermis, is a complex mixture of many different cell types - each with a very specific job. The production, or differentiation, of such a sophisticated tissue requires an immense amount of coordination at the cellular level, and glitches in the process can have disastrous consequences. Now, researchers at the Stanford University School of Medicine have identified a master regulator of this differentiation process.

2 Dec 2012

Researchers uncover molecular structure of master regulator central to melanoma

With the X-ray vision of DESY's light source DORIS, a research team from Hamburg and Iceland has uncovered the molecular structure of a master regulator central to the most deadly form of skin cancer, melanoma.

1 Dec 2012

iCAD introduces VersaVue Enterprise 3.2.1 MR software

iCAD, Inc., an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the identification and treatment of cancer, announced today it will launch VersaVue Enterprise 3.2.1, the latest release of the company's MR software solution that provides improvements in workflow efficiency and flexibility, at the annual conference of the Radiological Society of North America (RSNA) taking place in Chicago, November 25-30.

26 Nov 2012

Vitiligo patients have low risk for skin cancer

Evidence suggests that patients with vitiligo have a reduced risk for both melanoma and nonmelanoma skin cancer.

16 Nov 2012

Positive preliminary results from ImmunoPulse Phase II trial in metastatic melanoma

OncoSec Medical Inc., a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors, announces positive preliminary results from a Phase II trial investigating the use of ImmunoPulse in metastatic melanoma patients at the 6th World Meeting of Interdisciplinary Melanoma Skin Cancer Centres & 8th EADO Congress.

15 Nov 2012

Scientists eliminate metastasis in laboratory experiments

In laboratory experiments, scientists have eliminated metastasis, the spread of cancer from the original tumor to other parts of the body, in melanoma by inhibiting a protein known as melanoma differentiation associated gene-9 (mda-9)/syntenin. More than 1 million cases of skin cancer are diagnosed each year in the U.S., and melanoma is the deadliest form.

15 Nov 2012

Plexxikon updates Zelboraf Phase 1 data on BRAF V600E mutation-positive melanoma

Plexxikon today announced that updated Phase 1 clinical data of Zelboraf (vemurafenib) were presented at the Society for Melanoma Research (SMR) 2012 Congress, held November 8-11 in Los Angeles, CA.

8 Nov 2012

New UTSW model can predict progression of skin cancer in patients

UT Southwestern Medical Center scientists led by Dr. Sean Morrison, director of the Children's Medical Center Research Institute at UT Southwestern, have developed an innovative model for predicting the progression of skin cancer in patients.

8 Nov 2012

Vitamin D deficiency: an interview with Kellie Bilinski

We know that vitamin D is important in keeping bones strong. In the last 30-40 years it has also been realized that vitamin D has a lot of other roles in the body. Vitamin D essentially has a role in any cell in the body that has a vitamin D receptor.

5 Nov 2012

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

Bristol-Myers Squibb Company is pleased to announce that today the National Institute of Health and Clinical Excellence (NICE) has decided to recommend YERVOY (ipilimumab), which is approved in the European Union for the treatment of previously-treated metastatic (advanced) melanoma, within the Final Appraisal Determination (FAD).

3 Nov 2012

Regular blood test may help predict survival in patients with Merkel cell carcinoma

A routine blood test may help predict survival in patients with an aggressive form of skin cancer known as Merkel cell carcinoma, according to new findings by Fox Chase Cancer Center researchers. The results will be presented on Wednesday, October 31 at the American Society for Radiation Oncology's 54th Annual Meeting.

1 Nov 2012

Blocking RSK protein activity could improve treatment of skin cancers

Blocking the action of a particular protein in our skin could improve the treatment of skin cancers, according to a study published in Oncogene yesterday by Philippe Roux, a researcher at the University of Montreal's Institute for Research in Immunology and Cancer (IRIC).

31 Oct 2012

Zebrafish model can test unique individual genetic differences in humans

The zebrafish is a potential tool for testing one class of unique individual genetic differences found in humans, and may yield information helpful for the emerging field of personalized medicine, according to a team led by Penn State College of Medicine scientists. The differences, or mutations, in question create minor changes in amino acids -- the building blocks of DNA -- from person to person.

26 Oct 2012